Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241869 | 0.90 | SLC6A9 (0.49) | SLC6A9SCN8ASCN10ATACR1 | |
| SCHEMBL3903948 | 0.89 | SLC6A9 (0.48) | SLC6A9SCN8ASCN10ATACR1 | |
| Hydrochloric Acid SCHEMBL3910216 | 0.88 | SLC6A9 (0.48) | SLC6A9SCN8ASCN10ATACR1 | |
| SCHEMBL3238132 | 0.84 | SLC6A9 (0.51) | SLC6A9TACR1 | |
| SCHEMBL8265269 | 0.83 | SLC6A9 (0.48) | SLC6A9SCN8ASCN10A | |
| SCHEMBL3902101 | 0.83 | SLC6A9 (0.42) | SLC6A9SCN8ASCN10ATACR1 | |
| SCHEMBL3238430 | 0.83 | SLC6A9 (0.52) | SLC6A9TACR1 | |
| SCHEMBL3238355 | 0.81 | SLC6A9 (0.42) | SLC6A9TACR1 | |
| SCHEMBL3008740 | 0.81 | SLC6A9 (0.52) | SLC6A9TACR1 | |
| SCHEMBL29765315 | 0.81 | SLC6A9 (0.52) | SLC6A9TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 13/4885SCN8A 2635/4885SCN10A 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.